Article
Tamoxifen and risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: a case-control study. Hereditary Breast Cancer Clinical Study Group.
Lancet (London, England) - 2 Dec 2000
Narod S A, Brunet J S, Ghadirian P, Robson M, Heimdal K, Neuhausen S L, Stoppa-Lyonnet D, Lerman C, Pasini B, de los Rios P, Weber B, Lynch H
Abstract excerpt
BACKGROUND: Women with a mutation in BRCA1 or BRCA2 have a high risk of developing breast cancer and of contralateral cancer after the initial diagnosis of breast cancer. Tamoxifen protects against contralateral breast cancer in the general population, but whether it protects against contralateral breast cancer in BRCA1 or BRCA2 mutation carriers is not known. METHODS: We compared 209 women with bilateral breast...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.